Striatin plays a major role in angiotensin II-induced cardiomyocyte and cardiac hypertrophy in mice in vivo.
J. J. Cull, S. T. Cooper, H. O. Alharbi, S. Chothani, O. J. Rackham, D. N. Meijles, P. R. Dash, R. Kerkela, N. Ruparelia, P. H. Sugden, A. Clerk
Abstract
The three striatins (STRN, STRN3, STRN4) form the core of STRiatin-Interacting Phosphatase and Kinase (STRIPAK) complexes. These place protein phosphatase 2A (PP2A) in proximity to protein kinases thereby restraining kinase activity and regulating key cellular processes. Our aim was to establish if striatins play a significant role in cardiac remodelling associated with cardiac hypertrophy and heart failure. All striatins were expressed in control human hearts, with upregulation of STRN and STRN3 in failing hearts. We used mice with global heterozygote gene deletion to assess the roles of STRN and STRN3 in cardiac remodelling induced by angiotensin II (AngII; 7 days). Using echocardiography, we detected no differences in baseline cardiac function or dimensions in STRN+/- or STRN3+/- male mice (8 weeks) compared with wild-type littermates. Heterozygous gene deletion did not affect cardiac function in mice treated with AngII, but the increase in left ventricle mass induced by AngII was inhibited in STRN+/- (but not STRN3+/-) mice. Histological staining indicated that cardiomyocyte hypertrophy was inhibited. To assess the role of STRN in cardiomyocytes, we converted the STRN knockout line for inducible cardiomyocyte-specific gene deletion. There was no effect of cardiomyocyte STRN knockout on cardiac function or dimensions, but the increase in left ventricle mass induced by AngII was inhibited. This resulted from inhibition of cardiomyocyte hypertrophy and cardiac fibrosis. The data indicate that cardiomyocyte striatin is required for early remodelling of the heart by AngII and identify the striatin-based STRIPAK system as a signalling paradigm in the development of pathological cardiac hypertrophy. Clinical perspectivesO_LIBackground. Striatins form the core of STRiatin-Interacting Phosphatase And Kinase (STRIPAK) complexes that regulate crucial cellular processes such as those associated with heart failure. C_LIO_LISummary. The three striatins are expressed in human hearts, with upregulation of STRN and STRN3 in failing hearts, whilst studies in mice indicate that STRN is required in cardiomyocytes for early remodelling of the hypertensive heart. C_LIO_LIPotential significance of results to human health and disease. STRN-based STRIPAKs represent a novel signalling paradigm in the development of pathological cardiac hypertrophy, and modulating this system may provide therapeutic options for managing the cardiac effects of hypertensive heart disease. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- PKNs are required for cardiac hypertrophy induced by angiotensin II in mice
Susanna T.E. Cooper, Jacqueline J. T. Marshall, … Angela Clerk·bioRxiv·Oct 28, 2026
- Phosphoinositide Depletion and Compensatory β-adrenergic Signaling in Angiotensin II-Induced Heart Disease: Protection Through PTEN Inhibition
Taylor L. Voelker, Maartje Westhoff, … Rose Ellen Dixon·bioRxiv·Feb 23, 2025
- Systems analysis reveals neuregulin-1 control of cardiomyocyte size and shape mediated by distinct PI3K and p38 pathways
Pichayathida Luanpaisanon, Karen A. Ryall, … Jeffrey J. Saucerman·bioRxiv·Oct 1, 2025
- Regression from pathological hypertrophy is sexually dimorphic and stimulus-specific
Deanna Muehleman, Alison R. Swearingen, Leslie Anne Leinwand·bioRxiv·Jun 24, 2019
- PKN2 deficiency leads both to prenatal congenital cardiomyopathy and defective angiotensin II stress responses.
Jacqueline J. T. Marshall, Joshua J. Cull, … Peter J. Parker·Biochemical JournalPeer-reviewed·Jun 22, 2022
- Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice
H. O. Alharbi, M. A. Hardyman, … A. Clerk·bioRxiv·Sep 7, 2022